The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...

We estimate the NHS could potentially save £millions annually by greater use of the generic version of abiraterone rather than using enzalutamide and apalutamide, the other treatments we recommend at ...

This guidance is a partial review of NICE's diagnostics guidance on tumour profiling tests for guiding adjuvant chemotherapy decisions in early breast cancer (DG34) which made recommendations for ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Darolutamide, also known as Nubeqa and made by Bayer, is recommended in final draft guidance to treat adults with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation ...

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based ...

Suggested remit: To appraise the clinical and cost effectiveness of dostarlimab with platinum-based chemotherapy within its marketing authorisation for treating primary advanced or recurrent ...

All NICE products on oesophageal cancer. Includes any guidance and quality standards.

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

Suggested remit: To appraise the clinical and cost effectiveness of lecanemab within its marketing authorisation for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.